Stock Ratings / Health Care / CNMD / financials

CBLL (45) TMDX (69) INMD (74) AXGN (54) ⌘ Pro Terminal →

CONMED Corporation (CNMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$45.72 -0.09% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $45.63

CONMED Corporation (CNMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $1.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $45.62 (-0.21%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNMD)Realized 20D OHLCV Swing Band: ±9.3%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY CNMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (23% of score)

Altman Z-Score 1.91 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$44.42+5.2% Next Q

Q2 (-2Q)

Grade C$46.72+5.4% Next Q

Q3 (-1Q)

Grade C$49.25-7.2% Next Q

Current

Grade C$45.72+0.7% Hist 90D α

Trajectory: C- (54) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CNMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, CNMD faces multiple-compression risk if 28.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 52.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($47.08) or 200D SMA ($41.41) invalidates the momentum regime and cuts Target Base ($46.54) toward Bear Floor ($36.30).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CNMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$150.9M (11% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.24B

FY24

Rev $1.31B

FY25

Rev $1.37B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.37B	54.6%	7.5%	$47.1M	$150.9M	7.8%
FY 2024	$1.31B	56.1%	15.3%	$132.4M	$153.9M	16.4%
FY 2023	$1.24B	54.6%	9.7%	$64.5M	$125.3M	7.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNMD)

✓Walkthrough of CNMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.71%▼ SUPPORT BREAKDOWN

2026-10-30O $45.71H $46.33L $43.67C $45.72VOL 404.1K

RES: $49.46SUP: $46.81SMA50: $47.08SMA200: $41.41

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNMD Butterfly Map → + Track CNMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

22.2%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CNMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNMD)

Health Care Rank #170 of 1016 ⚔️ CBLL vs CNMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNMD vs. CBLL, TMDX, INMD, AXGN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CONMED Corporation (CNMD) ranks #170 by composite RQD confidence (62/100, grade C) and #318 by equity capitalization ($1.36B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. INMD currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CNMD at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNMD ACTIVE CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	Benchmark Subject
CBLL CeriBell Inc.	D	45/100	—	87.9%	-35.0%	+2.20%	$1.07B	/cbll-vs-cnmd →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-cnmd →
INMD InMode Ltd.	B	74/100	—	78.5%	17.7%	+1.05%	$776.6M	/inmd-vs-cnmd →
AXGN Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	/axgn-vs-cnmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000816956

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CONMED Corporation (CNMD) reported GAAP revenue of $1.37B (+5.2% vs. FY2024 revenue of $1.31B , and +10.4% cumulative change since FY2023) , GAAP net income of $47.1M, operating cash flow of $170.7M, and free cash flow of $150.9M (-2.0% YoY). On the balance sheet, CNMD closed FY2025 with $2.33B in total assets against $0 in total debt (Altman Z-Score: 1.91, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.37B	$47.1M	$170.7M	$150.9M	$2.33B	—
FY2024 (FY)	2024-12-31	$1.31B	$132.4M	$167.0M	$153.9M	$2.31B	—
FY2023 (FY)	2023-12-31	$1.24B	$64.5M	$125.3M	$125.3M	—	—

3. CNMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CONMED Corporation (NYSE: CNMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $45.72 (-0.09% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CNMD ranks #170 in composite RQD confidence.

How does CNMD compare to CBLL and TMDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CNMD carries a Roarable C (62/100 RQD), trailing P/E of 28.9x, gross margin of 54.6%, and ROIC of 7.8%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and TMDX (TransMedics Group Inc.) posts a C+ grade (69/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.33B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNMD?

Per CNMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000816956), CONMED Corporation generated $1.37B in revenue (+5.2% YoY), $47.1M in net income, and $150.9M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CNMD last traded at $45.72 (-0.09% on volume of 482,213 shares), positioning the stock -2.89% below its 50-day simple moving average ($47.08) and +10.41% above its 200-day simple moving average ($41.41). Across its 52-week range of $31.44 to $53.66, CNMD sits at the 64.3% percentile with a 14-day RSI of 40.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($41.47 to $49.97).

CNMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is CONMED Corporation (CNMD)?

In FY 2025 (10-K), CNMD converted $1.4B of revenue into a 54.6% gross margin, 7.5% operating margin, and $150.9M in free cash flow (11% FCF margin).

Direct Sub-Reports: CNMD RQD Cockpit CNMD 12M Forecast CNMD Earnings & Move CNMD Dividends & DRIP CNMD Insiders & 13F CNMD Whale Options CNMD Profit Sankey CNMD News & Why